Manifest hyperthyroidism in patient with autoimmune hepatitis (clinical observation)
https://doi.org/10.33667/2078-5631-2021-35-52-56
Abstract
Among patients with autoimmune hepatitis concomitant autoimmune diseases occur in 40 % of cases. The most commonly associated autoimmune hepatitis is primary biliary cholangitis, primary sclerosing cholangitis and thyroid disease. With regard to the association of autoimmune liver diseases with each other there is experience in management and this is reflected in the clinical guidelines. Information on the features of comorbidity in autoimmune hepatitis and autoimmune thyroid diseases is very limited. This article presents our own clinical observation of the manifestation of thyrotoxicosis against the background of autoimmune hepatitis.
About the Authors
M. A. Livzan
Omsk State Medical University
Russian Federation
Russian Federation
Livzan Maria A. - DM Sci (habil.), professor, rector, head of Dept of Faculty Therapy and Gastroenterology. Scopus ID: 24341682600
O. V. Gaus
Omsk State Medical University
Russian Federation
Russian Federation
Gaus Olga V. - PhD Med, associate professor at Dept of Faculty Therapy and Gastroenterology. Scopus ID: 56598554900
D. A. Gavrilenko
Omsk State Medical University
Russian Federation
Russian Federation
Gavrilenko Darya A. - 4th year student of the Faculty of Medicine
References
1. European Association for the Study of the Liver. EASL Clinical Practice Guide-lines: Autoimmune hepatitis. J Hepatol. 2015; 63 (4): 971–1004. https://doi.org/10.1016/j.jhep.2015.06.030
2. Zachou K., Muratori P., Koukoulis G. K., Granito A., Gatselis N., Fabbri A. et al. Review article: autoimmune hepatitis – current management and challenges. Aliment Pharmacol. Ther. 2013; 38 (8): 887–913. https://doi.org/10.1111/apt.12470
3. Stravitz R. T., Lefkowitch J. H., Fontana R. J., Gershwin M. E., Leung P. S., Sterling R. K., et al. Autoimmune acute liver failure: proposed clinical and his-tological criteria. Hepatology. 2011; 53 (2): 517–26. https://doi.org/10.1002/hep.24080
4. Kononov A. V., Livzan M. A. Evidence-based medicine in the practice of a clinical pathologist. Sibirskii Konsilium – Siberian Council. 2012; (2): 8–22.
5. Teufel A., Weinmann A., Kahaly G. J., Centner C., Piendl A., Wörns M. et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010; 44 (3): 208–13. https://doi.org/10.1097/MCG.0b013e3181c74e0d. PMID: 20087196
6. Muratori P., Fabbri A., Lalanne C., Lenzi M., Muratori L. Autoimmune liv-er disease and concomitant extrahepatic autoimmune disease. Eur. J. Gastroenterol. Hepatol. 2015; 27 (10): 1175–9. https://doi.org/10.1097/MEG.0000000000000424
7. Malik R., Hodgson H. The relationship between the thyroid gland and the liver. QJM. 2002; 95 (9): 559–69. https://doi.org/10.1093/qjmed/95.9.559
8. Korneeva O. N., Drapkina O. M., Pavlov Ch.S., Bakulin I. G. Ivashkin V. T. Non-alcoholic steatohepatitis in metabolic syndrome. Consillium Medium Magazine Supplement. 2007; (2): 18–21.
9. Upadhyay G., Singh R., Kumar A., Kumar S., Kapoor A., Godbole M. M. Severe hyperthyroidism induces mitochondria-mediated apoptosis in rat liver. Hepatology. 2004; 39 (4): 1120–30. https://doi.org/10.1002/hep.20085
10. Khemichian S., Fong T. L. Hepatic dysfunction in hyperthyroidism. Gastroen-terol Hepatol (N.Y.). 2011; 7 (5): 337–9.
11. Lin T. Y., Shekar A. O., Li N., Yeh M. W., Saab S., Wilson M. et al. Incidence of abnormal liver biochemical tests in hyperthyroidism. Clin. Endocrinol. (Oxf.). 2017; 86 (5): 755–759. https://doi.org/10.1111/cen.13312
12. Sato I., Tsunekawa T., Shinohara Y., Nishio Y., Shimizu Y., Suzuki Y., Yoshioka S. A case of autoimmune hepatitis with Graves' disease treated by propylthiouracil. Nagoya J. Med. Sci. 2011; 73 (3–4): 205–9.
13. Hsieh A., Adelstein S., McLennan S.V., Williams P. F., Chua E. L., Twigg S. M. Liver enzyme profile and progression in association with thyroid autoimmunity in Graves' disease. Endocrinol. Diabetes. Metab. 2019; 2 (4): e00086. https://doi.org/10.1002/edm2.86
14. Malespin M., Nassri A. Endocrine Diseases and the Liver: An Update. Clin. Liver. Dis. 2019; 23 (2): 233–246. https://doi.org/10.1016/j.cld.2018.12.006
15. Vitug A. C., Goldman J. M. Hepatotoxicity from antithyroid drugs. Horm. Res. 1985; 21 (4): 229–34. https://doi.org/10.1159/000180054
16. Liaw Y. F., Huang M. J., Fan K. D., Li K. L., Wu S. S., Chen T. J. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann. Intern. Med. 1993; 118 (6): 424–8. https://doi.org/10.7326/0003–4819–118–6–199303150–00005
17. Niculescu D. A., Dusceac R., Galoiu S. A., Capatina C. A., Poiana C. Serial changes of liver function tests before and during methimazole treatment in thyrotoxic patients. Endocr. Pract. 2016; 22 (8): 974–9. https://doi.org/10.4158/EP161222.OR
18. Burch H. B., Cooper D. S., Management of Graves Disease: A Review. JAMA. 2015; 314 (23): 2544–54. https://doi.org/10.1001/jama.2015.16535
19. Nakamura H., Noh J. Y., Itoh K., Fukata S., Miyauchi A., Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J. Clin. Endocrinol. Metab. 2007; 92 (6): 2157–62. https://doi.org/10.1210/jc.2006–2135
20. Ruiz J. K., Rossi G. V., Vallejos H. A., Brenet R. W., Lopez I. B., Escribano A. A. Ful-minant hepatic failure associated with propylthiouracil. Ann. Pharmacother. 2003; 37 (2): 224–8. https://doi.org/10.1177/106002800303700213
21. Ross D. S., Burch H. B., Cooper D. S., Greenlee M. C., Laurberg P., Maia A. L. et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26 (10): 1343–1421. https://doi.org/10.1089/thy.2016.0229
Review
For citations:
Livzan M.A., Gaus O.V., Gavrilenko D.A. Manifest hyperthyroidism in patient with autoimmune hepatitis (clinical observation). Medical alphabet. 2021;(35):52-56. (In Russ.) https://doi.org/10.33667/2078-5631-2021-35-52-56
Views:
354
Email this article 